Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Wuhan HealthCare Biotechnology (WHV) is a high-tech enterprise specializing in the research, development, and manufacturing of advanced molecular diagnostic products. The company is best known for its proprietary FastProbe technology, which significantly reduces the hybridization time for Fluorescence in situ hybridization (FISH) from the traditional 16-24 hours to just 2 hours. WHV offers a comprehensive portfolio of diagnostic kits targeting oncology, hematology, and prenatal screening, including probes for HER2, ALK, and ROS1. Headquartered in Wuhan, China, the company operates a GMP-certified facility and serves clinical laboratories and hospitals globally. Their mission is to provide rapid, accurate, and cost-effective diagnostic solutions to improve patient outcomes in precision medicine.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on WHV.